Opciones terapéuticas y EII
Rodríguez-Lago I, Sempere L, Gutiérrez A, Núñez A, Leo Carnerero E, Hinojosa E, et al.
Scand J Gastroenterol. 2019
2. Effectiveness and safety of the switch from Remicade to CT-P13 in patients with inflammatory bowel disease.
Chaparro M, Garre A, Guerra Veloz MF, Vázquez JM, De Castro ML, Leo E, et al.
J Crohns Colitis. 2019
Complicaciones
1. Cases report: severe colonic bleeding in ulcerative colitis is refractory to selective transcatheter arterial embolization.
Miranda-Bautista J, Diéguez L, Rodríguez-Rosales G, Marín-Jiménez I, Menchén L.
BMC Gastroenterol. 2019
2. Nivolumab-induced immune-mediated colitis: an ulcerative colitis look-alike-report of new cases and review of the literature.
Cañete F, Mañosa M, Lobatón T, Mesonero F, Rodríguez-Lago I, Cabré E, et al.
Int J Colorectal Dis. 2019
3. Paradoxical Arthritis in Inflammatory Bowel Diasease Patients on Ustekinumab Treatment.
García García MJ, Rivero Tirado M, Callizo MEP.
Inflamm Bowel Dis. 2019
4.Steroids and postoperative complications in IBD.
López-Sanromán A.
Curr Drug Targets. 2019
Epidemiología
1. Prevalence of ten Immune-mediated inflammatory diseases (IMID) in Spain.
Puig L, Ruiz de Morales JG, Dauden E, Andreu JL, Cervera R, Adán A, Marsal S, Escobar C, Hinojosa J, Palau J, Arraiza A, Casado P, Codesido M, Pascual C, Saldaña R, Gil Á.
Rev Esp Salud Publica. 2019
Telemedicina
The Harvey-Bradshaw Index Adapted to a Mobile Application Compared with In-Clinic Assessment: The MediCrohn Study.
Echarri A, Vera I, Ollero V, Arajol C, Riestra S, Robledo P, et al.
Telemed J E Health. 2019
Percepciones del paciente. Impacto y calidad de vida. Recomendaciones
1. A Prospective Pilot Randomized Study: Electroacupuncture vs. Sham Procedure for the Treatment of Fatigue in Patients With Quiescent Inflammatory Bowel Disease.
Horta D, Lira A, Sanchez-Lloansi M, Villoria A, Teggiachi M, García-Rojo D, García-Molina S, et al.
Inflamm Bowel Dis. 2019 May 15
2. Bases for the Adequate Development of Nutritional Recommendations for Patients with Inflammatory Bowel Disease.
Sáez-González E, Mateos B, López-Muñoz P, Iborra M, Moret I, Nos P, Beltrán B.
Nutrients. 2019 May 12
3. Impact and risk factors of non-adherence to 5-aminosalicylates in quiescent ulcerative colitis evaluated by an electronic management system.
Ballester MP, Marti-Aguado D, Fullana M, Bosca-Watts MM, Tosca J, Romero E, Sanchez A, Navarro-Cortes P, Anton R, Mora F, Minguez M.
Int J Colorectal Dis. 2019
4. The experience of inflammatory bowel disease patients with healthcare: A survey with the IEXPAC instrument.
Marín-Jiménez I, Casellas F, Cortés X, García-Sepulcre MF, Juliá B, Cea-Calvo L, et al.
Medicine (Baltimore). 2019
Factores y predicción de respuesta y progresión . Metodos diagnósticos
1. Comparison of a new rapid method for the determination of adalimumab serum levels with two established ELISA kits.
Laserna-Mendieta EJ, Salvador-Martín S, Arias-González L, Ruiz-Ponce M, Menchén LA, Sánchez C, et al.
Clin Chem Lab Med. 2019 May 14
PMID: 3108574
2. Relationship between serum adalimumab levels and clinical outcome in the treatment of inflammatory bowel disease.
Hinojosa J, Muñoz J, Martinez-Romero Gj
Dig Dis 2019
3. Endoscopic response to tumor necrosis factor inhibitors predicts long term benefits in Crohn´s disease.
Alfaro I, Masamunt MC, Planell N, López-García A, Castro J, Gallego M et al.
World J Gastroenterol. 2019
4. A Nomogram Combining Fecal Calprotectin Levels and Plasma Cytokine Profiles for Individual Prediction of Postoperative Crohn’s Disease Recurrence.
Cerrillo E, Moret I, Iborra M, Pamies J, Hervás D, Tortosa L, Sáez-González E, Nos P, Beltrán B.
Inflamm Bowel Dis. 2019
5. Actual Anti-TNF Trough Levels Relate to Serum IL-10 in Drug-Responding Patients With Crohn’s Disease.
Zapater P, Almenara S, Gutiérrez A, Sempere L, García M, Laveda R, et al.
Inflamm Bowel Dis. 2019
6. Influence of Vitamin D Deficiency on Inflammatory Markers and Clinical Disease Activity in IBD Patients.
López-Muñoz P, Beltrán B, Sáez-González E, Alba A, Nos P, Iborra M.
Nutrients. 2019 May 11
7. Prognostic Value of the Burden of Cytomegalovirus Colonic Reactivation Evaluated by Immunohistochemical Staining in Patients with Active Ulcerative Colitis.
Clos-Parals A, Rodríguez-Martínez P, Cañete F, Mañosa M, Ruiz-Cerulla A, José Paúles M, Llaó J, Gordillo J, Fumagalli C, Garcia-Planella E, Ojanguren I, Cabré E, Guardiola J, Domènech E.
J Crohns Colitis. 2019
8. Clinical Impact of Sonographic Transmural Healing After Anti-TNF Antibody Treatment in Patients with Crohn’s Disease.
Paredes JM, Moreno N, Latorre P, Ripollés T, Martinez MJ, Vizuete J, Moreno-Osset E.
Dig Dis Sci. 2019
9. Development and Validation of a Simplified Magnetic Resonance Index of Activity for Crohn’s disease.
Ordás I, Rimola J, Alfaro I, Rodríguez S, Castro-Poceiro J, Ramírez-Morros A, Gallego M, Giner À, Barastegui R, Fernández-Clotet A, Masamunt M, Ricart E, Panés J.
Gastroenterology. 2019
Genetica, inmunología, proteómica
1. Genetic association between CD96 locus and immunogenicity to anti-TNF therapy in Crohn’s disease.
Aterido A, Palau N, Domènech E, Nos Mateu P, Gutiérrez A, Gomollón F, et al.
Pharmacogenomics J. 2019
Pediatría
1. Development and Validation of the Mucosal Inflammation Noninvasive Index For Pediatric Crohn’s Disease.
Cozijnsen MA, Ben Shoham A, Kang B, Choe BH, Choe YH, Jongsma MME, Russell RK, Ruemmele FM, Escher JC, de Ridder L, Koletzko S, Martín-de-Carpi J, Hyams J, Walters T, Griffiths A, Turner D.
Clin Gastroenterol Hepatol. 2019
2. Designing clinical trials in paediatric inflammatory bowel diseases: a PIBDnet commentary.
Turner D, Griffiths AM, Wilson D, Mould DR, Baldassano RN, Russell RK, Dubinsky M, Heyman MB, de Ridder L, Hyams J, Martin de Carpi J, Conklin L, Faubion WA, Koletzko S, Bousvaros A, Ruemmele FM.
Gut 2019
3. Central Venous Sinus Thrombosis in a Boy With Acute Severe Ulcerative Colitis.
Martín-Masot R, Ortiz Pérez P, Serrano Nieto J, Martínez León M, Pascual Martínez A, Blasco-Alonso J, Navas-López VM.
Front Pediatr. 2019
4. Transition Care Program of Adolescents With Inflammatory Bowel Disease: Perceptions From A Survey for Patients.
Blázquez ML, Hernani MT, Calatayud GÁ, González-Pinto LC, Menchén L, Jiménez IM, García BG, Calleja AL, Sánchez CS.
Inflamm Bowel Dis. 2019
Guías clínicas
1. European Crohn’s and Colitis Organisation Topical Review on Complementary Medicine and Psychotherapy in Inflammatory Bowel Disease.
Torres J, Ellul P, Langhorst J, Mikocka-Walus A, Barreiro-de Acosta M, Basnayake C, et al.
J Crohns Colitis. 2019
